The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Anamorelin is a ghrelin receptor agonist that can be administered orally and thought to improve cancer cachexia by improving appetite and increasing serum insulin‐like growth factor‐1. Anamorelin was not approved for use in Europe. In contrast, the use of anamorelin for cancer cachexia in four types of cancer (non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer) was approved in Japan on 11 December 2020. Phase 2 trial (ONO‐7643‐04) for the treatment of patients with non‐small cell lung cancer and cachexia resulted in 1.56 kg lean body mass increase assessed by dual‐energy X‐ray absorptiometry (DXA). Another study for advanced and unresectable gastrointestinal (colorectal, gastric, or pancreatic) cancer showed 1.89 ± 0.36 kg improvement in lean body mass. Skeletal lean body mass assessed by DXA is important for diagnosing sarcopenia and cachexia in Asia. The approval of anamorelin is expected to change clinical practice of cancer cachexia in Japan and hopefully in other countries. In the past, cachexia was rarely diagnosed in Japan, because it was often thought that cachexia meant terminal stage. The dissemination of clinical findings on anamorelin from Japan, as well as the creation of consensus papers and clinical practice guidelines for cachexia in Japan and Asia, will be required to promote international expansion in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 2×
“Anamorelin Placebo P value Mean (kg) SD (kg) Mean (kg) SD (kg) Katakami et al.(4) 1.”
BackgroundAsian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 1×
“Assessment of lean body mass by DXA is not recommended for sarcopenia diagnosis in the Sarcopenia Definition and Outcomes Consortium position statements(13) but is included in the Asian Working Group for Sarcopenia 2019 consensus.(14) Skeletal lean body mass assessed by DXA is important for diagnosing sarcopenia and c…”
BackgroundSelf-citationSarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium
Bhasin, S., Travison, T. G., Manini, T. M., Patel, S., Pencina, K. M., Fielding, R. A., Magaziner, J. M., Newman, A. B., Kiel, D. P., Cooper, C., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16372 · Cited by 723
Self-citationTemel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., et al. (2018) · Cancer · doi:10.1002/cncr.31128 · Cited by 239
Cited by
Argilés, J. M., López-Soriano, F. J., Stemmler, B., & Busquets, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00734-5 · Cited by 246
Cancer Cachexia: Its Mechanism and Clinical Significance
Nishikawa, H., Goto, M., Fukunishi, S., Asai, A., Nishiguchi, S., & Higuchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168491 · Cited by 233
“Based on these results, anamorelin has been approved for the treatment of cancer cachexia in Japan.”
BackgroundInfluentialCurrent and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Anamorelin in Japanese patients with cancer cachexia: an update
Wakabayashi, H., Arai, H., & Inui, A. (2023) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0000000000000658 · Cited by 17
Self-citation
Metadata
- Authors
- Wakabayashi, H., Arai, H., & Inui, A.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2020-12-31
- Volume
- 12
- Issue
- 1
- Pages
- 14-16
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W3115452618
- Cited by
- 161
- References
- 5
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. https://app.cochat.ai/papers/10.1002/jcsm.12675
- The paper
- Wakabayashi, H., Arai, H., & Inui, A. (2021). The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12675
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.